Daclatasvir dihydrochloride

DRUG2 trials

Sponsors

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Conditions

Drug InteractionsHepatitis C, Chronic

Phase 1

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

CompletedNCT03748745

Nanjing Sanhome Pharmaceutical, Co., Ltd.Drug Interactions

Start: 2018-11-19End: 2018-12-25Updated: 2019-08-13

Phase 2

SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C

Nanjing Sanhome Pharmaceutical, Co., Ltd.Hepatitis C, Chronic

Start: 2019-03-29End: 2020-08-31Target: 440Updated: 2019-08-28

Related Papers

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

Infectious Diseases and Therapy2023-10-194 citations

Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study

Journal of Viral Hepatitis2022-01-266 citations